Association between prophylactic low‐molecular‐weight heparin use in pregnancy and macrosomia: analysis of the Ottawa and Kingston birth cohort
Author(s): ,
D. E. Lowry
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada
,
D. J. Corsi
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
,
R. R. White
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada
,
M. Guo
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada
,
A. Lanes
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada
,
G. Smith
Affiliations:
Department of Obstetrics and Gynecology, Queen's Perinatal Research Unit, Kingston General Hospital, Queens University, Kingston, Canada
,
M. Rodger
Affiliations:
Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Canada
,
S. W. Wen
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
,
M. Walker
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada. Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Canada
L. Gaudet
Affiliations:
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada. Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Canada
Correspondence: Laura Gaudet, Ottawa Hospital Research Institute, Center for Practice Changing Research, 501 Smyth Road, Box 241, Ottawa, ON K1H 8L6, Canada|Tel.: +1 613 737 8899 (x73056)|E‐mail: lagaudet@toh.ca
ISTH Academy. Gaudet L. Feb 8, 2019; 273379
Laura Gaudet
Laura  Gaudet
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

Click here to join ISTH or renew your membership.

You may also access ISTH content "anytime, anywhere" with the FREE ISTH Academy App for iOS and Android.
Journal Abstract
Discussion Forum (0)
Rate & Comment (0)


Background
Low‐molecular‐weight heparin (LMWH), an anticoagulant, is the recommended drug for thromboprophylaxis and treatment of venous thromboembolism (VTE) in pregnancy. During pregnancy, LMWH is routinely prescribed to mothers with an increased risk of VTE or with a history of thrombosis. Although clinical reports of larger offspring born to women administered LMWH have been noted, no studies to date have evaluated or associated the use of LMWH and large for gestational age (LGA) infants.
Objectives
To determine whether there is an association between LMWH usage in mothers and the prevalence of LGA.
Patients/Methods
We performed an analysis of the Ottawa and Kingston (OaK) Birth Cohort and report characteristics of LMWH and association LGA (> 10%ile). We used coarsened exact matching (CEM) methods to account for bias and confounding.
Results
A total of 7519 women from the OaK Birth Cohort were included; 59 were administered LMWH during pregnancy (0.78%). Mothers prescribed LMWH had significantly greater BMI (P = 0.0001), age (P = 0.0001) and parity (P = 0.02). Gestational length was shorter among women administered LMWH compared to those without treatment (37.7 ± 2.0 vs. 39.2 ± 2.0, P < 0.0001), an iatrogenic finding. The odds ratio of an LGA delivery among women administered LMWH was 1.02 (95% confidence interval [CI], 0.48–2.16; P = 0.96) in unadjusted analyses and was 1.15 (95% CI, 0.49–2.71) in the matched sample adjusted for maternal age, BMI and gestational age.
Conclusions
These results, although exploratory, provide indirect evidence of no increased risk of LGA infants among women prescribed LMWH.
Keyword(s)
large for gestational age, low‐molecular‐weight heparin (LWMH), macrosomia, pregnancy, prophylaxis, venous thromboembolism (VTE)
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies